The results of the KEGG study have indicated that the main pathways of SAHP in migraine therapy are related to neuroactive ligand-receptor interaction, calcium signaling pathways, pathways in cancer, cAMP signaling pathways, and PI3K-Akt signaling pathways. This evidence concerns the gene PIK3CB and migraine disorder.